Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine vs Methotrexate in Pediatric Alopecia Areata (COMPARE)
NCT07381556Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, single-blind trial of cyclosporine and methotrexate in alopecia areata (2 arms), sponsored by Erasmus MC. Primary endpoint: Severity of Alopecia Tool at 36 weeks. Started Nov 2025; status: recruiting.
02
Drugs
cyclosporinemethotrexate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT07381556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07381556.